Incyte Corporation (NASDAQ:INCY) headquartered in Wilmington, will host a conference call for the investment community to discuss the 2Q20 earnings result on 4th August 2020 at 8:00 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.incyte.com
Earnings Expectation
Incyte Corporation proprietary therapeutics in oncology, is reporting second quarter earnings results on Tuesday 4th August 2020, before market open. The consensus estimates from Thomson Reuters are income of $ 0.88 per share. For the full year, analysts predict revenues of $ 2459.99 million, while looking forward to loss of $ 0.45 per share.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis.
